

## Clinical and molecular aspects of senataxin mutations in ALS4

Christopher Grunseich, MD <sup>1\*</sup>, Aneesh Patankar, BSc <sup>1</sup>, Joshua Amaya, BSc <sup>1</sup>, Jason A. Watts, MD, PhD <sup>3</sup>, Dongjun Li, M.D. <sup>2,5</sup>, Prisila Ramirez, BSc <sup>2</sup>, Alice B. Schindler, MSc, CGC <sup>1</sup>, Kenneth H. Fischbeck, MD <sup>1</sup>, Vivian G. Cheung, MD <sup>2,4,5\*</sup>

Running head: Clinical and molecular characterization in ALS4

<sup>1</sup> Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA

<sup>2</sup> Life Sciences Institute, University of Michigan, Ann Arbor, MI, USA

<sup>3</sup> Department of Medicine, University of Michigan, Ann Arbor, MI, USA

<sup>4</sup> Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA

<sup>5</sup> Howard Hughes Medical Institute, Chevy Chase, MD, USA

\* Please send correspondence to CG ([christopher.grunseich@nih.gov](mailto:christopher.grunseich@nih.gov)); 2A-1010, 35 Convent Drive, Bld. 35, National Institutes of Health, Bethesda, MD 20892; ph 301-402-5423

Title character count (58), Running head character count (47)

Word count: abstract (240), introduction (273), discussion (606), body (3084)

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1002/ana.25681](https://doi.org/10.1002/ana.25681)

**Abstract**

**Objective:** To determine the clinical and molecular features in patients with ALS4 and mutations in the senataxin (*SETX*) gene, and to develop tools for evaluating *SETX* variants.

**Methods:** Our study involved 32 patients, including 31 with mutation in *SETX* at c.1166 T>C (p.Leu389Ser) and one with mutation at c.1153 G>A (p.Glu385Lys). Clinical characterization of the patients included neurological examination, blood tests, magnetic resonance imaging (MRI), and dual-energy X-ray absorptiometry (DEXA). Fibroblasts and motor neurons were obtained to model the disease and characterize the molecular alteration in senataxin function.

**Results:** We report key clinical features of ALS4. Laboratory analysis showed alteration of serum creatine kinase and creatinine in the Leu389Ser ALS4 cohort. MRI showed increased muscle fat fraction in the lower extremities which correlates with disease duration (thigh fat fraction  $R^2 = 0.35$ ,  $p = 0.01$ , lower leg fat fraction  $R^2 = 0.49$ ,  $p < 0.01$ ). DEXA measurements showed lower extremities are more affected than the upper extremities (average fat Z-scores of 2.1 and 0.6, respectively). A cellular assay for *SETX* function confirmed that like the Leu389Ser mutation, the Glu385Lys variant leads to a gain of senataxin function and thus a decrease in R-loops.

**Interpretation:** We identified clinical laboratory and radiological features of ALS4, and hence they should be monitored for disease progression. The molecular characterization of R-loop levels in patient-derived cells provides insight into the disease pathology and assays to evaluate the pathogenicity of candidate mutations in the *SETX* gene.

## Introduction

Amyotrophic lateral sclerosis (ALS) is a collection of neurodegenerative disorders characterized by loss of upper and lower motor neurons. A subgroup of ALS has been found to be caused by genetic mutations.<sup>1</sup> Among the mutated genes are those that encode RNA processing proteins, including TDP-43, FUS, hnRNPA1, and hnRNPA2B1.<sup>2,3,4</sup> Identification of these mutations has improved our understanding of how RNA synthesis and post-transcriptional processing affect motor neuron pathophysiology.

There is a range of manifestations in ALS, including age of onset and rate of progression. The heterogeneity poses diagnostic challenges and impedes patient care. As genetic testing becomes available, more diagnoses of genetic forms of the disease have been made. However, interpretation of the results is not always simple. And even when the results are clear, most of the genetic forms of ALS are rare, and the clinical course and manifestations are not well characterized. This lack of information hampers genetic counseling and assessment of disease prognosis, and it limits evaluation of outcome in clinical trials.

A genetic form of ALS that faces these challenges is ALS4, an autosomal dominant disorder caused by mutations in the senataxin (*SETX*) gene.<sup>5,6,7,8</sup> *SETX* is a large gene that encodes a 303 kD helicase which resolves RNA-DNA hybrids. It is often difficult to determine whether a particular sequence variant is pathogenic as affected family members may not be available for segregation analysis, or the variant may be a de novo mutation. Here we examined and followed patients from one large ALS4 pedigree and one unrelated patient to characterize the

clinical signs, identify biomarkers, and develop a molecular assay to assess the functional effects of sequence variants in *SETX*.

## **Methods**

### **Patient Population**

*SETX* mutations were confirmed in 31 patients, with the mutation Leu389Ser and one patient with the variant Glu385Lys. All subjects received clinical evaluations at the National Institutes of Health (NIH) in Bethesda, MD under IRB-approved protocol 00-N-0043 “Clinical and Molecular Manifestations of Inherited Neurological Disorders.” Written informed consent was received from all participants before inclusion in the study. Laboratory testing and clinical evaluations were done at the NIH clinical center. Muscle strength was evaluated using the Medical Research Council (MRC) scale.

### **Radiological Testing**

Seventeen ALS4 patients (10 females and 7 males) had T1-weighted leg imaging in a 1.5-T MR scanner at the NIH clinical center. Nine of these subjects (5 females and 4 males) had followup MRI scans. Images for thigh muscle quantification included a 10cm region around the midpoint between the head of the femur and the cartilage meniscus of the knee. For the lower leg, the quantified images included a 6cm region around a point one-third of the distance from the cartilage meniscus of the knee to the articular cartilage of the tibial-talus joint. A semi-

automated code with FIJI software was used to quantify the area of contractile (hypointense) and non-contractile (hyperintense) tissue with the “auto local threshold” function and the Phansalkar method for each image sequence.<sup>9</sup> Manual image segmentation of tissue area was done for bone marrow, compact bone, and subcutaneous adipose tissue in each image. Fat fraction was calculated as the ratio of non-contractile tissue to total tissue area in the thigh muscle and leg muscle compartments.

DEXA whole body composition measurements were obtained at NIH Clinical Center Radiology, and Z-scores were calculated using normative data from the NHANES dataset.<sup>10</sup>

### **Motor Neuron Characterization**

Induced pluripotent stem cells (iPSCs) were generated from dermal fibroblasts from biopsy of the ventral forearm from two healthy controls. Fibroblasts were cultured as previously described.<sup>11</sup> A third control iPSC line (WTC11) was obtained from the Coriell Institute. Stem cells were differentiated into motor neuron-like cells by stable insertion of an inducible transcription factor cassette expressing neurogenin-2 (NGN2), islet-1 (ISL1), and LIM homeobox 3 (LHX3) (hNIL) into the *CLYBL* safe harbor locus as previously described.<sup>12</sup> Differentiation was initiated using DMEM/F12 media containing N2 supplement, non-essential amino acids, L-glutamine, 10  $\mu$ M ROCK inhibitor, 0.2  $\mu$ M compound E, and 2  $\mu$ g/mL doxycycline. After 2 days of differentiation, the cells were dissociated with accutase and plated on poly-l-ornithine coated dishes in DMEM/F12 media containing N2 supplement, non-essential

amino acids, L-glutamine, B27 supplement, 10 ng/ml BDNF, and 1  $\mu$ g/mL laminin (density of 10,000 cells per well of a 96 well plate for TGF $\beta$  characterization). The cells were treated with TGF $\beta$  (20 ng/mL, R+D Systems) beginning at 2 days of differentiation with 50% media changes at 2 day intervals. Morphologic analysis was done on images acquired with a 20X objective and Nikon Ti-E motorized fluorescence microscope. Nikon's NIS-Element Advanced Research (AR) software was used to mask the cell somas and neurites. Neurite length and number of branch points were quantified from 5 wells (25 images/well) of a 96-well plate for each sample, and normalized to the soma count.

### **Senataxin Assays**

Control fibroblasts were transfected with plasmids corresponding to wild type (WT) and *SETX* variants for 1 day before collection and S9.6 dot blot. Samples for immunofluorescence were fixed 2 days after transfection with 4% paraformaldehyde for 15 minutes at room temperature, and motor neurons were fixed for 10 minutes with 4% paraformaldehyde containing 4% sucrose and then quenched in 100 mM glycine for 5 minutes. Fixed cells were then washed three times with phosphate-buffered saline (PBS) as previously described.<sup>11</sup> The cells were stained with the following antibodies: S9.6 antibody (gift from Stephen Leppia), 1:500 HB9 antibody (DSHB), 1:500 SETX (Novus), or 1:2000 SMI-32 (Abcam). Quantification of staining by ImageJ was done by observers blinded to the genotypes of the samples.

## S9.6 Dot Blot

Genomic DNA was phenol extracted, ethanol precipitated, and reconstituted in 12  $\mu$ L TE buffer. 2  $\mu$ l DNA solution (100ng) was loaded to Hybond N+ nylon membrane (GE Life Sciences) presoaked with PBS, and crosslinked in UV Stratalinker 2400 (Stratagene) at the “Auto Crosslink” setting (1200  $\mu$ JoulesX100). The membrane was blocked in 5% milk in TBS-0.05% Tween-20 for one hour and incubated with 1:1000 S9.6 antibody overnight at 4°C to detect RNA-DNA hybrids. A duplicate blot was incubated with anti-dsDNA antibody (Abcam) as loading control. dsDNA, double-stranded RNA and RNA-DNA hybrid controls were annealed using synthetic oligos reported previously.<sup>13</sup> ssRNA, top strand: 5'-UGGGGGCUCGUCCGGGAUAUGGGAACCACUGAUCCC-3'; ssDNA, top strand: 5'-TGGGGGCTCGTCCGGGATATGGGAACCACTGATCCC-3'; ssDNA, bottom strand: 5'-GGGATCAGTGGTTCCCATATCCCGGACGAGCCCCCA-3'; ssRNA, bottom strand: 5'-GGGAUCAGUGGUUCCCAUAUCCCGGACGAGCCCCCA-3'.

## mRNA Expression and Western Blot Analysis

RNA extracted and analyzed as previously described.<sup>11</sup> Briefly, 1  $\mu$ g total RNA was converted to cDNA using the High Capacity cDNA Reverse Transcriptase kit (Applied Biosystems) and *BAMBI* expression levels were evaluated with Taqman probe (Hs03044164\_m1) with *HPRT1* Taqman probe (Hs02800695\_m1) as a control. Western blots were done with antibodies for SETX (Bethyl), pSMAD2 and SMAD2/3 (Cell Signaling Tech.), vinculin (Abcam), and lysates



prepared in RIPA buffer (50 mM Tris, pH8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS).

## **Results**

### **Genetic Evaluation**

Thirty of the 31 subjects were members of a large pedigree.<sup>6</sup> All affected members were confirmed to have the Leu389Ser mutation in *SETX*. Another unrelated patient was evaluated for a history of difficulty with walking since age 4, necessitating the use of leg braces at age 8. She had developed hand weakness at age 10. Genetic testing identified a Glu385Lys (heterozygous c.1153 G>A) change close to the previously described *SETX* mutation. The variant was not present in the ExAC sequencing database, and predicts substitution of an amino acid conserved across mammalian species (Fig 1A,B). We previously showed that the Leu389Ser mutation does not affect senataxin expression.<sup>11</sup> We found similar *SETX* protein expression and cellular localization in Glu385Lys patient cells as in cells from two unrelated controls (Fig 1C,D).

### **Physical Examination**

The demographics of the 31 patients (14 males and 17 females) with Leu389Ser ALS4 in this study are shown in Supplemental Table 1. The average age at the time of evaluation was 42

years. Sixty-five percent of patients reported having at least one fall within the past year. The average age of onset of weakness was 16 years. On physical examination, a majority of patients (87%) was found to have hyperreflexia, and 7 (23%) had a Babinski reflex. Manual muscle strength testing using the MRC scale was done on all 31 patients, including 14 who had additional follow-up visits over an average of 3 years. Muscle weakness was found in 24 patients (77%), and muscle wasting in 19 (61%). The pattern of weakness was mostly symmetric, with evidence of asymmetry (greater than 1 unit MRC difference between the left and right side) in only 3 patients. Of the 24 patients with extremity weakness, 14 had both proximal and distal involvement, and the remaining 10 had only a distal distribution. None of the patients had proximal weakness only. With increasing disease duration, we found progressive reduction in ankle dorsiflexion ( $R^2 = 0.31$ ,  $p < 0.0001$ ) and plantarflexion ( $R^2 = 0.12$ ,  $p < 0.01$ ). Seven patients had decreased sensation to at least one modality with a distal pattern of involvement. Three patients reported mild symptoms of dysphagia with infrequent choking, and no patients were found to have dysarthria. Only one patient was found to have bulbar weakness with involvement of the orbicularis oris and hypoglossal muscles. Additionally, evidence of ataxia with dysmetria or past pointing in the upper extremities was found in about half of the patients. Evidence of ocular apraxia was detected in only two patients.

The patient with Glu385Lys SETX variant was found to have atrophy and weakness in her distal upper and lower extremities (Fig 1E). She was unable to extend her fingers against

gravity, and had no movement in her ankles or toes. Reflexes were brisk diffusely in her upper and lower extremities and plantar reflexes were absent.

### **Laboratory Findings**

Laboratory analysis showed a significant increase in serum creatine kinase (CK) in both males (ALS4 mean 420 U/L  $\pm$  105 SEM, N=11 vs. control mean 177 U/L  $\pm$  3 SEM, N=1141;  $p < 0.0001$ ) and females (ALS4 mean 182 U/L  $\pm$  42 SEM, N=11 vs. control mean 106 U/L  $\pm$  3 SEM, N=491;  $p < 0.0001$ ). The male subjects also had a significant decrease in creatinine levels compared to healthy controls (ALS4 mean 0.56 mg/dL  $\pm$  0.09 SEM, N=8 vs. control mean 1.02 mg/dL  $\pm$  0.03 SEM, N=73;  $p < 0.0001$ ). There were no significant differences in the serum hormone levels in the male or female Leu389Ser ALS patients compared to controls. The Glu385Lys ALS4 patient had normal CK and reduced creatinine levels (0.33 mg/dL).

### **Electrophysiology**

Nerve conduction studies and electromyography in 13 patients with Leu389Ser and one patient with Glu385Lys showed prolonged distal motor latencies, decreased CMAP amplitudes, and chronic neurogenic changes. A length-dependent sensory neuropathy was detected in one patient.

### **Radiographic Findings**

To determine the extent of muscle damage, we used quantitative MRI to measure fat replacement of skeletal muscle. T1-weighted scans of the lower extremities were performed on 17 patients. The results showed a positive correlation between disease duration and muscle fat fraction in the thigh ( $R^2 = 0.35$ ,  $p = 0.01$ ) and lower leg ( $R^2 = 0.49$ ,  $p < 0.01$ ) (Fig 2A,B) consistent with muscle atrophy. We measured bone densitometry and lean body mass in 12 subjects with DEXA. Half the patients were found to have reduced overall lean body mass with a Z-score of  $< -1$  (Fig 2C+D). In particular, the average lean body mass in the extremities was reduced with an average Z-score of  $-1.7$ . The lower extremities were found to be more severely involved compared to the upper extremities with increased fat replacement and average fat Z-scores of  $2.1$  and  $0.6$ , respectively (Fig 2E). MRI of the Glu385Lys patient showed muscle loss and diffuse fatty infiltration in muscles of the thigh and distal lower extremities (Fig 2F), and appendicular lean body mass was significantly reduced (Z-score =  $-5.7$ ) on DEXA.

### **Other Findings**

Eight patients had benign and malignant tumors, including 5 colonic polyps (1 with polyps of both the uterus and colon), two adenocarcinomas of the colon, and one of the lung. One patient with adenocarcinoma of the colon was a 35 year old male, a relatively early onset given that the disease frequency is just  $0.4\%$  in men under the age of 49.<sup>14</sup> The benign polyps were also found in individuals under age 49. In light of these findings it is noteworthy that *SETX* mutations were

found in 7% of colorectal tumors in the Cancer Genome Atlas,<sup>15</sup> comparable to the rate of mutations in DNA mismatch-repair pathway genes *MLH1* (3%), *MSH3* (7%), and *MSH6* (8%).

### **Characterization of TGF $\beta$ Biology in Fibroblasts and Stem-Cell Derived Motor Neurons**

We previously found that the TGF $\beta$  pathway is activated in Leu389Ser ALS4 patient fibroblasts with reduced expression of BAMBI, a negative regulator of the pathway.<sup>11</sup> Here, we measured and found that the expression level of *BAMBI* was also reduced in the patient with Glu385Lys mutation ( $p < 0.01$ ; Fig 3A). In order to characterize the impact of TGF $\beta$  on motor neurons, we derived motor neuron-like cells from control iPSCs. iPSCs expressing markers of pluripotency were genotyped to confirm the stable heterozygous integration of the hNIL cassette into the *CLYBL* locus. Motor neuron-like identity was confirmed by the expression of the homeobox gene *HB9*<sup>17</sup> and the neurofilament marker, *SMI32*<sup>18</sup> within one week of differentiation (Fig 3B).

We treated the iPSC-derived cells with TGF $\beta$  and confirmed activation of the pathway by an increase of SMAD2 phosphorylation (Fig 3C). The neurons with TGF $\beta$  treatment showed a significant reduction in neurite length and branching after one week of differentiation ( $p < 0.0001$ , Fig 4A-C) consistent with a toxic effect of TGF $\beta$  activation.

### **R-Loop Assays**

Molecular characterization of patient fibroblasts with the Leu389Ser mutation previously showed a reduction of nuclear R-loops in patient fibroblasts and motor neurons.<sup>11</sup> R-loops are three-

stranded nucleic acid structures that form when nascent RNA hybridizes with its template DNA to form an RNA-DNA hybrid and displaces the non-template DNA strand. Senataxin is a helicase that resolves R-loops.<sup>19,20</sup> An antibody, S9.6, is used in many studies to characterize R-loops.<sup>21</sup> To demonstrate the specificity and sensitivity of the S9.6 antibody for R-loops, we first probed synthetic hybrids of dsRNA, dsDNA, or RNA-DNA hybrid with the S9.6 antibody (Fig 5A). S9.6 signal was specific to RNA-DNA hybrid, and signal intensity was reduced with decreasing amounts of RNA-DNA hybrid. We evaluated R-loop abundance in the Glu385Lys patient fibroblasts and found a significant decrease compared to controls by S9.6 dot blot ( $p < 0.05$ ) (Fig 5B).

To confirm that the reduction in R-loop abundance is a consequence of the SETX variant, we overexpressed the wild-type and mutant forms of SETX in control fibroblasts. Overexpression of the Glu385Lys and Leu389Ser mutations resulted in a significant reduction in nuclear R-loop structure by immunofluorescence compared to transfection of WT senataxin alone ( $p < 0.01$ ; Fig 5C). Overexpression of a 500 amino acid N-terminal WT fragment of senataxin without the helicase domain or other non-pathogenic variants with high allele frequency (Lys827Glu, ExAC allele frequency 0.001) did not reduce R-loop levels. Dot blot analysis of cells overexpressing SETX variants, including the previously reported Arg2136His ALS4 variant<sup>5</sup>, showed a reduction in S9.6 signal intensity when compared to WT SETX (Fig 5D).

## Discussion

Defining the appropriate molecular and clinical biomarkers for disease characterization and progression are crucial steps to understanding and treating neurological disease. In this study, we identified clinical and molecular characteristics of ALS4 caused by heterozygous mutations in the *SETX* gene.

Relative to other forms of ALS, the onset for ALS4 is early. The average age of onset in our cohort is 17 years old which is consistent with the previous clinical characterization of patients with mutation at codon 389 of *SETX*.<sup>6,22</sup> In ALS4, males are more affected than females. Rafiq et al. also found a significantly greater increase in male ALS patient serum CK levels compared to females.<sup>23</sup> A previous study of ALS4 patients found a higher percentage of asymptomatic females (31%) compared to males (13%).<sup>6</sup>

As a motor neuron disease, ALS4 leads to progressive muscle loss. We found significantly higher serum CK and lower creatinine levels. Elevation of serum CK levels is also known to occur in patients with sporadic ALS.<sup>23</sup> Among our ALS4 cohort, the male patients have significantly lower creatinine levels which reflects a greater disease burden in males. Serum creatinine level have been reported to change significantly during the progression of other motor neuron diseases.<sup>24,25</sup> Radiological studies showed higher thigh muscle fat fraction and lower lean body mass. ALS4 patients have fatty infiltration in the muscles of their lower extremities. Previously, we found a reduction in contractile muscle volume in a smaller cohort of ALS4 patients.<sup>11</sup> The pattern of lean body mass on DEXA analysis supports that the lower

extremities are more severely affected than the upper extremities. Manual muscle testing also showed a reduction in lower leg strength with disease duration. The greater severity of lower extremity involvement in ALS4 was first described by Rabin et al., 1999.<sup>6</sup> The increased fat replacement of muscle is likely related to a loss of lean body mass and disuse, and has been found to correlate with disease status in other studies.<sup>26</sup> Together these data suggest MRI of the lower leg for fatty infiltration to the muscles may be a useful study to follow for evidence of disease progression.

We found a similar pattern of clinical and radiological changes in a patient with mutation in SETX codon 385. Consistent with the gain of function in SETX helicase activity and reduction in R-loop levels that had been detected in patients with mutation at Leu389Ser,<sup>11</sup> the Glu385Lys SETX variant was also associated with a reduction in R-loop levels. Expression levels of BAMBI, a negative regulator of TGF $\beta$  activity, were also found to be reduced in the Glu385Lys SETX patient fibroblasts.

SETX function has been shown to modulate neuromuscular junction plasticity in *Drosophila* through the TGF $\beta$  pathway.<sup>27</sup> TGF signaling has been found to inhibit neurite elongation and branching in neuronal cell models<sup>28</sup>, and to promote disease progression in the SOD1 mouse model of ALS by disrupting the neuroprotective functions of activated glial and immune cells.<sup>29</sup> Here, we show that exogenous TGF $\beta$  treatment of control iPSC-derived motor neurons resulted in a reduction in motor neuron neurite length and branching, indicating that activation of the TGF $\beta$  pathway adversely affects motor neurons.



In conclusion, this study of 32 subjects with mutations in senataxin establishes the clinical and molecular features of an inherited form of upper and lower motor neuron disease. We also developed measurement of R-loop levels and BAMBI expression as assays for interrogating the potential pathogenicity of *SETX* variants. Further studies with other mutations in the *SETX* gene causing ALS4 are needed to more thoroughly evaluate the clinical and molecular spectrum. Additional longitudinal data are also needed to determine the clinical course, molecular effects and assess heterogeneity of the disease.

**Acknowledgements:** We thank Dr. Stephen Lepla for the S9.6 antibody. We thank Ms. Elizabeth Hartnett for her help in scheduling patients during the study and the clinical staff of the outpatient NIH neurology clinic for assistance during the patients' visits. We thank the National Institutes of Health NHLBI iPS cell core facility for the generation of stem cell lines. We thank the Howard Hughes Medical Institute and intramural National Institute of Neurological Disorders and Stroke for funding this work. We are grateful for the active participation of the patients and their families; without their involvement and encouragement this project would not have been possible.

**Author Contributions:** C.G., K.H.F., and V.G.C. contributed to the conception and design of the study. C.G., A.P., J.A., P.R., D.L., J.A.W., and A.B.S. contributed to the acquisition and analysis of data. C.G., K.H.F., and V.G.C. contributed to drafting the manuscript and figures.

**Potential Conflicts of Interest:** Nothing to report.

Author Manuscript

## References

1. Ghasemi M, Brown RH Jr. Genetics of Amyotrophic Lateral Sclerosis. *Cold Spring Harb Perspect Med* 2018;8:5.
2. Gitcho MA, Baloh RH, Chakraverty S et al. TDP-43 A315T mutation in familial motor neuron disease. *Ann Neurol* 2008;63:535-538.
3. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. *Science* 2009;323:1205-1208.
4. Kim HJ, Kim NC, Wang YD et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. *Nature* 2013;495:467-473.
5. Chen YZ, Bennett CL, Huynh HM et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). *Am J Hum Genet* 2004;74:1128-1135.
6. Rabin BA, Griffin JW, Crain BJ et al. Autosomal dominant juvenile amyotrophic lateral sclerosis. *Brain* 1999;122:1539-1550.
7. Hirano M, Quinzii CM, Mitsumoto H et al. Senataxin mutations and amyotrophic lateral sclerosis. *Amyotroph Lateral Scler* 2011;12:223-227.
8. Bassuk AG, Chen YZ, Batish SD et al. In cis autosomal dominant mutation of senataxin associated with tremor/ataxia syndrome. *Neurogenetics* 2007;8:45-49.
9. Phansalkar, N; More, S & Sabale, A et al. Adaptive local thresholding for detection of nuclei in diversity stained cytology images. *International Conference on Communications and Signal Processing (ICCSP)* 2011;218-220.
10. Kelly TL, Wilson KE, Heymfield SB. Dual energy X-Ray absorptiometry body composition reference values from NHANES. *PLoS One* 2009;4:e7038.
11. Grunseich C, Wang IX, Watts JA et al. Senataxin mutation reveals how R-loops promote transcription by blocking DNA methylation at gene promoters. *Mol Cell* 2018;69:426-437.
12. Fernandopulle MS, Prestil R, Grunseich C, Wang C, Gan L, Ward ME. Transcription factor-mediated differentiation of human iPSCs into neurons. *Curr Protoc Cell Biol.* 2018;79:e51

13. Haruki M, Noguchi E, Kanaya S, Crouch RJ. Kinetic and stoichiometric analysis for the binding of Escherichia coli ribonuclease HI to RNA-DNA hybrids using surface plasmon resonance. *J Biol Chem* 1997;272:22015-22022.
14. Cancer facts and figures 2019, American Cancer Society.  
[www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf](http://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf) Updated 2019. Accessed July 1, 2019
15. The cancer genome atlas, National human genome research institute,  
[www.cancergenome.nih.gov](http://www.cancergenome.nih.gov) Updated 2019. Accessed June 1, 2018
16. Cerbini T, Funahashi R, Luo Y et al. Transcription activator-like effector nuclease (TALEN)-mediated CLYBL targeting enables enhanced transgene expression and one-step generation of dual reporter human induced pluripotent stem cell (iPSC) and neural stem cell (NSC) lines. *PLoS One* 2015;10:e0116032.
17. Arber S, Han B, Mendelsohn M, Smith M, Jessell TM, Sockanathan S. Requirement for the homeobox gene Hb9 in the consolidation of motor neuron identity. *Neuron* 1999;23:659-674.
18. Carriedo SG, Yin HZ, Weiss JH. Motor neurons are selectively vulnerable to AMPA/kainite receptor-mediated injury in vitro. *J Neurosci* 1996;16:4069-4079.
19. Kim HD, Choe J, Seo YS. The sen1(+) gene of Schizosaccharomyces pombe, a homologue of budding yeast SEN1, encodes an RNA and DNA hemicase. *Biochemistry* 1999;38:14697-14710.
20. Skourti-Stathaki K, Proudfoot NJ, Gromak N. Human senataxin resolves RNA/DNA hybrids formed at transcriptional pause sites to promote Xrn2-dependent termination. *Mol Cell* 2011;42:794-805.
21. Hu Z, Zhang A, Storz G, Gottesman S, Leppla SH. An antibody-based microarray assay for small RNA detection. *Nucleic Acids Res* 2006;34:e52.
22. Avemaria F, Lunetta C, Tarlarini C, et al. Mutation in the senataxin gene found in a patient affected by familial ALS with juvenile onset and slow progression. *Amyotroph Lateral Scler* 2011;12:228-230.
23. Rafiq MK, Lee E, Bradburn M, McDermott CJ, Shaw PJ. Creatine kinase enzyme level correlates positively with serum creatinine and lean body mass, and is a prognostic factor for survival in amyotrophic lateral sclerosis. *Eur J Neurol* 2016;23:1071-1078.

24. Patin F, Corcia P, Madji Hounoum B, et al. Biological follow-up in amyotrophic lateral sclerosis: decrease in creatinine levels and increase in ferritin levels predict poor prognosis. *Eur J Neurol* 2015;22:1385-1390.
25. Hashizume A, Katsuno M, Banno H et al. Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy. *Brain* 2012;135:2838-2848.
26. Dahlqvist JR, Oestergaard ST, Poulsen NS, Thomsen C, Vissing J. Refining the spinobulbar muscular atrophy phenotype by quantitative MRI and clinical assessments. *Neurology* 2019;92:e548-e559.
27. Mushtaq Z, Choudhury SD, Gangwar SK, Orso G, Kumar V. Human senataxin modulates structural plasticity of the neuromuscular junction in drosophila through a neuronally conserved TGF $\beta$  signaling pathway. *Neurodegener Dis* 2016;16:324-336.
28. Nakashima H, Tsujimura K, Irie K, et al. Canonical TGF- $\beta$  signaling negatively regulates neuronal morphogenesis through TGFIF/Smad complex-mediated CRMP2 suppression. *J Neurosci* 2018;38:4791-4810.
29. Endo F, Komine O, Fujimori-Tonou N et al. Astrocyte-derived TGF- $\beta$ 1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells. *Cell Rep* 2015;11:592-604.

**Legend**

**Figure 1:** Glu385Lys mutation in senataxin (SETX). (A) The amino acid sequence at position 385 of SETX is conserved across species. (B) Map of helicase domain and nuclear localization signal (NLS) showing the location of the three previously known mutations causing ALS4 (Tyr3Ile, Leu389Ser, and Arg2136His) and the Glu385Lys variant. (C) Western blot of SETX from fibroblast cultures of two controls and the Glu385Lys patient. Vinculin was used as a loading control. (D) Immunofluorescence staining for SETX (green) in two controls and patient fibroblasts. DAPI staining in blue. Scale bar, 5 $\mu$ m. (E) Atrophy in the interossei muscles of the hand and involuntary abduction of the fifth finger.

**Figure 2:** Clinical measurements in ALS4 patients with mutation at codon 389. (A) T1 MRI image of the thigh muscle with segmented non-contractile tissue in black. Compact bone and bone marrow removed from fat fraction calculation. (B) Disease duration is significantly

correlated with MRI muscle fat fraction from the thigh ( $R^2 = 0.35$ ;  $p = 0.01$ ) and lower leg ( $R^2 = 0.49$ ;  $p < 0.01$ ). (C) Dual-energy X-ray absorptiometry imaging in an ALS4 patient showing relative preservation of lean body mass (red) in the upper compared to the lower extremities. (D) Distribution of Z-scores shows a significant reduction in appendicular lean body mass (-1.7) and increase (E) in average leg (2.1) vs. arm (0.6) fat Z-scores. Z-scores calculated using National Health and Nutrition Examination Survey (NHANES) reference controls. Black dotted line indicates the Z-score 1 standard deviation below (D) or above (E) the mean. (F) T1 MRI imaging of the thigh showing fatty infiltration and loss of contractile tissue in the thigh (left) and lower leg (right).

**Figure 3:** TGF $\beta$  activity in patient fibroblasts and motor neuron characterization. (A) Reduced *BAMBI* transcript expression in Glu385Lys patient fibroblasts compared to 2 controls. Error bars are SEM of triplicates.  $**p < 0.01$  (t test). (B) Immunofluorescence staining from three control iPSC cell lines differentiated by expression of the human Neurogenin 2, Islet 1, and LIM Homeobox 3 (hNIL) transgene cassette. HB9 staining (green) in motor neuron nuclei, SMI-32 (cyan) in motor neuron processes, DAPI staining in blue. Staining is at 5 days post differentiation. Scale bar, 25 $\mu$ m. (C) Western blot analysis of pSMAD2 and SMAD2/3 levels in iPSC motor neurons treated with 0, 5, and 20 ng/mL TGF $\beta$ .

**Figure 4:** Morphological analysis of TGF $\beta$  treated motor neurons. (A) Fluorescence imaging of control motor neuron lines with and without TGF $\beta$  treatment. TGF $\beta$  treated motor neurons have reduced neurite length (B) and branching (C). N= 6, 5 wells analyzed per sample, error bars are SEM. Scale bar, 50 $\mu$ m. error bars are SEM. \*\*\*\*p < 0.0001; (t test).

**Figure 5:** R-loop assessments of senataxin dysfunction. (A) S9.6 antibody dot blot against a dilution series of synthetic dsRNA, dsRNA, and RNA/DNA hybrids. (B) Dot blot probed with S9.6 antibody shows fewer R-loops in Glu385Lys patient fibroblasts compared to two age and sex matched controls. A duplicate blot probed with anti-dsDNA antibody was used as loading control. Error bars are SEM of triplicates. \*p < 0.05 (t test). (C) Immunofluorescence staining showing reduced nuclear S9.6 (green) in cells transfected with Leu389Ser and Glu385Lys forms of SETX compared to WT. Scale bar, 5 $\mu$ m, R-loops in nuclei indicated by arrow. 10 fields per sample, 15-20 cells per field; error bars are SEM. \*\*\*\*p < 0.0001; \*\*p < 0.01 (t test). (D) Quantification of dot blot S9.6 signal in cells transfected with WT, Leu389Ser, Glu385Lys, and Arg2136His forms of SETX. Samples normalized to dsDNA loading control. Error bars are SEM of triplicates. \*p < 0.05, \*\*p < 0.01 (t test).






Figure 1


A

Homo sapiens AICPDYCPNMYE\*EMETLASVLQSDI  
Pan troglodytes AICPDYCPNMYEEMETLASVLQSDI  
Macaca mulatta AICPDYCPNMYEEMETLASVLQSDI  
Canis lupus AICPDYCPNMYEEMETLASVLQSDI  
Bos taurus AICPDYCPNMYEEMETLANVLQSDI  
Mus musculus AICPDYCPNMYEEMETLANVLQSDI  
Rattus norvegicus AICPDYCPNMYEEMETLANVLQSDI  
Patient AICPDYCPNMYEKMETLASVLQSDI


B



C



D



E



**Figure 2**




Figure 3




Figure 4





Figure 5



## Clinical and molecular aspects of senataxin mutations in ALS4

Christopher Grunseich, MD <sup>1\*</sup>, Aneesh Patankar, BSc <sup>1</sup>, Joshua Amaya, BSc <sup>1</sup>, Jason A. Watts, MD, PhD <sup>3</sup>, Dongjun Li, M.D. <sup>2,5</sup>, Prisila Ramirez, BSc <sup>2</sup>, Alice B. Schindler, MSc, CGC <sup>1</sup>, Kenneth H. Fischbeck, MD <sup>1</sup>, Vivian G. Cheung, MD <sup>2,4,5\*</sup>

Running head: Clinical and molecular characterization in ALS4

<sup>1</sup> Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA

<sup>2</sup> Life Sciences Institute, University of Michigan, Ann Arbor, MI, USA

<sup>3</sup> Department of Medicine, University of Michigan, Ann Arbor, MI, USA

<sup>4</sup> Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA

<sup>5</sup> Howard Hughes Medical Institute, Chevy Chase, MD, USA

\* Please send correspondence to CG ([christopher.grunseich@nih.gov](mailto:christopher.grunseich@nih.gov)); 2A-1010, 35 Convent Drive, Bld. 35, National Institutes of Health, Bethesda, MD 20892; ph 301-402-5423

Title character count (58), Running head character count (47)

Word count: abstract (240), introduction (273), discussion (606), body (3084)

**Abstract**

**Objective:** To determine the clinical and molecular features in patients with ALS4 and mutations in the senataxin (*SETX*) gene, and to develop tools for evaluating *SETX* variants.

**Methods:** Our study involved 32 patients, including 31 with mutation in *SETX* at c.1166 T>C (p.Leu389Ser) and one with mutation at c.1153 G>A (p.Glu385Lys). Clinical characterization of the patients included neurological examination, blood tests, magnetic resonance imaging (MRI), and dual-energy X-ray absorptiometry (DEXA). Fibroblasts and motor neurons were obtained to model the disease and characterize the molecular alteration in senataxin function.

**Results:** We report key clinical features of ALS4. Laboratory analysis showed alteration of serum creatine kinase and creatinine in the Leu389Ser ALS4 cohort. MRI showed increased muscle fat fraction in the lower extremities which correlates with disease duration (thigh fat fraction  $R^2 = 0.35$ ,  $p = 0.01$ , lower leg fat fraction  $R^2 = 0.49$ ,  $p < 0.01$ ). DEXA measurements showed lower extremities are more affected than the upper extremities (average fat Z-scores of 2.1 and 0.6, respectively). A cellular assay for *SETX* function confirmed that like the Leu389Ser mutation, the Glu385Lys variant leads to a gain of senataxin function and thus a decrease in R-loops.

**Interpretation:** We identified clinical laboratory and radiological features of ALS4, and hence they should be monitored for disease progression. The molecular characterization of R-loop levels in patient-derived cells provides insight into the disease pathology and assays to evaluate the pathogenicity of candidate mutations in the *SETX* gene.



## Introduction

Amyotrophic lateral sclerosis (ALS) is a collection of neurodegenerative disorders characterized by loss of upper and lower motor neurons. A subgroup of ALS has been found to be caused by genetic mutations.<sup>1</sup> Among the mutated genes are those that encode RNA processing proteins, including TDP-43, FUS, hnRNPA1, and hnRNPA2B1.<sup>2,3,4</sup> Identification of these mutations has improved our understanding of how RNA synthesis and post-transcriptional processing affect motor neuron pathophysiology.

There is a range of manifestations in ALS, including age of onset and rate of progression. The heterogeneity poses diagnostic challenges and impedes patient care. As genetic testing becomes available, more diagnoses of genetic forms of the disease have been made. However, interpretation of the results is not always simple. And even when the results are clear, most of the genetic forms of ALS are rare, and the clinical course and manifestations are not well characterized. This lack of information hampers genetic counseling and assessment of disease prognosis, and it limits evaluation of outcome in clinical trials.

A genetic form of ALS that faces these challenges is ALS4, an autosomal dominant disorder caused by mutations in the senataxin (*SETX*) gene.<sup>5,6,7,8</sup> *SETX* is a large gene that encodes a 303 kD helicase which resolves RNA-DNA hybrids. It is often difficult to determine whether a particular sequence variant is pathogenic as affected family members may not be available for segregation analysis, or the variant may be a de novo mutation. Here we examined and followed patients from one large ALS4 pedigree and one unrelated patient to characterize the clinical signs, identify biomarkers, and develop a molecular assay to assess the functional effects of sequence variants in *SETX*.

## **Methods**

### **Patient Population**

*SETX* mutations were confirmed in 31 patients, with the mutation Leu389Ser and one patient with the variant Glu385Lys. All subjects received clinical evaluations at the National Institutes of Health (NIH) in Bethesda, MD under IRB-approved protocol 00-N-0043 “Clinical and Molecular Manifestations of Inherited Neurological Disorders.” Written informed consent was received from all participants before inclusion in the study. Laboratory testing and clinical evaluations were done at the NIH clinical center. Muscle strength was evaluated using the Medical Research Council (MRC) scale.

### **Radiological Testing**

Seventeen ALS4 patients (10 females and 7 males) had T1-weighted leg imaging in a 1.5-T MR scanner at the NIH clinical center. Nine of these subjects (5 females and 4 males) had followup MRI scans. Images for thigh muscle quantification included a 10cm region around the midpoint between the head of the femur and the cartilage meniscus of the knee. For the lower leg, the quantified images included a 6cm region around a point one-third of the distance from the cartilage meniscus of the knee to the articular cartilage of the tibial-talus joint. A semi-automated code with FIJI software was used to quantify the area of contractile (hypointense) and non-contractile (hyperintense) tissue with the “auto local threshold” function and the Phansalkar method for each image sequence.<sup>9</sup> Manual image segmentation of tissue area was done for bone marrow, compact bone, and subcutaneous adipose tissue in each image. Fat fraction was calculated as the ratio of non-contractile tissue to total tissue area in the thigh muscle and leg muscle compartments.

DEXA whole body composition measurements were obtained at NIH Clinical Center Radiology, and Z-scores were calculated using normative data from the NHANES dataset.<sup>10</sup>

### **Motor Neuron Characterization**

Induced pluripotent stem cells (iPSCs) were generated from dermal fibroblasts from biopsy of the ventral forearm from two healthy controls. Fibroblasts were cultured as previously described.<sup>11</sup> A third control iPSC line (WTC11) was obtained from the Coriell Institute. Stem cells were differentiated into motor neuron-like cells by stable insertion of an inducible transcription factor cassette expressing neurogenin-2 (NGN2), islet-1 (ISL1), and LIM homeobox 3 (LHX3) (hNIL) into the *CLYBL* safe harbor locus as previously described.<sup>12</sup>

Differentiation was initiated using DMEM/F12 media containing N2 supplement, non-essential amino acids, L-glutamine, 10  $\mu$ M ROCK inhibitor, 0.2  $\mu$ M compound E, and 2  $\mu$ g/mL doxycycline. After 2 days of differentiation, the cells were dissociated with accutase and plated on poly-l-ornithine coated dishes in DMEM/F12 media containing N2 supplement, non-essential amino acids, L-glutamine, B27 supplement, 10 ng/ml BDNF, and 1  $\mu$ g/mL laminin (density of 10,000 cells per well of a 96 well plate for TGF $\beta$  characterization). The cells were treated with TGF $\beta$  (20 ng/mL, R+D Systems) beginning at 2 days of differentiation with 50% media changes at 2 day intervals. Morphologic analysis was done on images acquired with a 20X objective and Nikon Ti-E motorized fluorescence microscope. Nikon's NIS-Element Advanced Research (AR) software was used to mask the cell somas and neurites. Neurite length and number of branch points were quantified from 5 wells (25 images/well) of a 96-well plate for each sample, and normalized to the soma count.

## Senataxin Assays

Control fibroblasts were transfected with plasmids corresponding to wild type (WT) and *SETX* variants for 1 day before collection and S9.6 dot blot. Samples for immunofluorescence were fixed 2 days after transfection with 4% paraformaldehyde for 15 minutes at room temperature, and motor neurons were fixed for 10 minutes with 4% paraformaldehyde containing 4% sucrose and then quenched in 100 mM glycine for 5 minutes. Fixed cells were then washed three times with phosphate-buffered saline (PBS) as previously described.<sup>11</sup> The cells were stained with the following antibodies: S9.6 antibody (gift from Stephen Leppa), 1:500 HB9 antibody (DSHB), 1:500 SETX (Novus), or 1:2000 SMI-32 (Abcam). Quantification of staining by ImageJ was done by observers blinded to the genotypes of the samples.

## S9.6 Dot Blot

Genomic DNA was phenol extracted, ethanol precipitated, and reconstituted in 12  $\mu$ L TE buffer. 2  $\mu$ l DNA solution (100ng) was loaded to Hybond N+ nylon membrane (GE Life Sciences) presoaked with PBS, and crosslinked in UV Stratalinker 2400 (Stratagene) at the “Auto Crosslink” setting (1200  $\mu$ JoulesX100). The membrane was blocked in 5% milk in TBS-0.05% Tween-20 for one hour and incubated with 1:1000 S9.6 antibody overnight at 4°C to detect RNA-DNA hybrids. A duplicate blot was incubated with anti-dsDNA antibody (Abcam) as loading control. dsDNA, double-stranded RNA and RNA-DNA hybrid controls were annealed using synthetic oligos reported previously.<sup>13</sup> ssRNA, top strand: 5'-UGGGGGCUCGUCCGGGAUAUGGGAACCACUGAUCCC-3'; ssDNA, top strand: 5'-TGGGGGCTCGTCCGGGATATGGGAACCACTGATCCC-3'; ssDNA, bottom strand: 5'-

GGGATCAGTGGTTCCCATATCCCGGACGAGCCCCCA-3'; ssRNA, bottom strand: 5'-  
GGGAUCAGUGGUUCCCAUAUCCCGGACGAGCCCCCA-3'.

### **mRNA Expression and Western Blot Analysis**

RNA extracted and analyzed as previously described.<sup>11</sup> Briefly, 1 µg total RNA was converted to cDNA using the High Capacity cDNA Reverse Transcriptase kit (Applied Biosystems) and *BAMBI* expression levels were evaluated with Taqman probe (Hs03044164\_m1) with *HPRT1* Taqman probe (Hs02800695\_m1) as a control. Western blots were done with antibodies for SETX (Bethyl), pSMAD2 and SMAD2/3 (Cell Signaling Tech.), vinculin (Abcam), and lysates prepared in RIPA buffer (50 mM Tris, pH8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS).

### **Results**

#### **Genetic Evaluation**

Thirty of the 31 subjects were members of a large pedigree.<sup>6</sup> All affected members were confirmed to have the Leu389Ser mutation in *SETX*. Another unrelated patient was evaluated for a history of difficulty with walking since age 4, necessitating the use of leg braces at age 8. She had developed hand weakness at age 10. Genetic testing identified a Glu385Lys (heterozygous c.1153 G>A) change close to the previously described *SETX* mutation. The variant was not present in the ExAC sequencing database, and predicts substitution of an amino acid conserved across mammalian species (Fig 1A,B). We previously showed that the Leu389Ser mutation does not affect senataxin expression.<sup>11</sup> We found similar SETX protein

expression and cellular localization in Glu385Lys patient cells as in cells from two unrelated controls (Fig 1C,D).

### **Physical Examination**

The demographics of the 31 patients (14 males and 17 females) with Leu389Ser ALS4 in this study are shown in Supplemental Table 1. The average age at the time of evaluation was 42 years. Sixty-five percent of patients reported having at least one fall within the past year. The average age of onset of weakness was 16 years. On physical examination, a majority of patients (87%) was found to have hyperreflexia, and 7 (23%) had a Babinski reflex. Manual muscle strength testing using the MRC scale was done on all 31 patients, including 14 who had additional follow-up visits over an average of 3 years. Muscle weakness was found in 24 patients (77%), and muscle wasting in 19 (61%). The pattern of weakness was mostly symmetric, with evidence of asymmetry (greater than 1 unit MRC difference between the left and right side) in only 3 patients. Of the 24 patients with extremity weakness, 14 had both proximal and distal involvement, and the remaining 10 had only a distal distribution. None of the patients had proximal weakness only. With increasing disease duration, we found progressive reduction in ankle dorsiflexion ( $R^2 = 0.31$ ,  $p < 0.0001$ ) and plantarflexion ( $R^2 = 0.12$ ,  $p < 0.01$ ). Seven patients had decreased sensation to at least one modality with a distal pattern of involvement. Three patients reported mild symptoms of dysphagia with infrequent choking, and no patients were found to have dysarthria. Only one patient was found to have bulbar weakness with involvement of the orbicularis oris and hypoglossal muscles. Additionally, evidence of ataxia with dysmetria or past pointing in the upper extremities was found in about half of the patients. Evidence of ocular apraxia was detected in only two patients.

The patient with Glu385Lys SETX variant was found to have atrophy and weakness in her distal upper and lower extremities (Fig 1E). She was unable to extend her fingers against gravity, and had no movement in her ankles or toes. Reflexes were brisk diffusely in her upper and lower extremities and plantar reflexes were absent.

### **Laboratory Findings**

Laboratory analysis showed a significant increase in serum creatine kinase (CK) in both males (ALS4 mean 420 U/L  $\pm$  105 SEM, N=11 vs. control mean 177 U/L  $\pm$  3 SEM, N=1141;  $p < 0.0001$ ) and females (ALS4 mean 182 U/L  $\pm$  42 SEM, N=11 vs. control mean 106 U/L  $\pm$  3 SEM, N=491;  $p < 0.0001$ ). The male subjects also had a significant decrease in creatinine levels compared to healthy controls (ALS4 mean 0.56 mg/dL  $\pm$  0.09 SEM, N=8 vs. control mean 1.02 mg/dL  $\pm$  0.03 SEM, N=73;  $p < 0.0001$ ). There were no significant differences in the serum hormone levels in the male or female Leu389Ser ALS patients compared to controls. The Glu385Lys ALS4 patient had normal CK and reduced creatinine levels (0.33 mg/dL).

### **Electrophysiology**

Nerve conduction studies and electromyography in 13 patients with Leu389Ser and one patient with Glu385Lys showed prolonged distal motor latencies, decreased CMAP amplitudes, and chronic neurogenic changes. A length-dependent sensory neuropathy was detected in one patient.

### **Radiographic Findings**

To determine the extent of muscle damage, we used quantitative MRI to measure fat replacement of skeletal muscle. T1-weighted scans of the lower extremities were performed on 17 patients. The results showed a positive correlation between disease duration and muscle fat fraction in the thigh ( $R^2 = 0.35$ ,  $p = 0.01$ ) and lower leg ( $R^2 = 0.49$ ,  $p < 0.01$ ) (Fig 2A,B) consistent with muscle atrophy. We measured bone densitometry and lean body mass in 12 subjects with DEXA. Half the patients were found to have reduced overall lean body mass with a Z-score of  $< -1$  (Fig 2C+D). In particular, the average lean body mass in the extremities was reduced with an average Z-score of  $-1.7$ . The lower extremities were found to be more severely involved compared to the upper extremities with increased fat replacement and average fat Z-scores of  $2.1$  and  $0.6$ , respectively (Fig 2E). MRI of the Glu385Lys patient showed muscle loss and diffuse fatty infiltration in muscles of the thigh and distal lower extremities (Fig 2F), and appendicular lean body mass was significantly reduced (Z-score =  $-5.7$ ) on DEXA.

### **Other Findings**

Eight patients had benign and malignant tumors, including 5 colonic polyps (1 with polyps of both the uterus and colon), two adenocarcinomas of the colon, and one of the lung. One patient with adenocarcinoma of the colon was a 35 year old male, a relatively early onset given that the disease frequency is just 0.4% in men under the age of 49.<sup>14</sup> The benign polyps were also found in individuals under age 49. In light of these findings it is noteworthy that *SETX* mutations were found in 7% of colorectal tumors in the Cancer Genome Atlas,<sup>15</sup> comparable to the rate of mutations in DNA mismatch-repair pathway genes *MLH1* (3%), *MSH3* (7%), and *MSH6* (8%).

### **Characterization of TGF $\beta$ Biology in Fibroblasts and Stem-Cell Derived Motor Neurons**



We previously found that the TGF $\beta$  pathway is activated in Leu389Ser ALS4 patient fibroblasts with reduced expression of BAMBI, a negative regulator of the pathway.<sup>11</sup> Here, we measured and found that the expression level of *BAMBI* was also reduced in the patient with Glu385Lys mutation ( $p < 0.01$ ; Fig 3A). In order to characterize the impact of TGF $\beta$  on motor neurons, we derived motor neuron-like cells from control iPSCs. iPSCs expressing markers of pluripotency were genotyped to confirm the stable heterozygous integration of the hNIL cassette into the *CLYBL* locus. Motor neuron-like identity was confirmed by the expression of the homeobox gene HB9<sup>17</sup> and the neurofilament marker, SMI32<sup>18</sup> within one week of differentiation (Fig 3B).

We treated the iPSC-derived cells with TGF $\beta$  and confirmed activation of the pathway by an increase of SMAD2 phosphorylation (Fig 3C). The neurons with TGF $\beta$  treatment showed a significant reduction in neurite length and branching after one week of differentiation ( $p < 0.0001$ , Fig 4A-C) consistent with a toxic effect of TGF $\beta$  activation.

### **R-Loop Assays**

Molecular characterization of patient fibroblasts with the Leu389Ser mutation previously showed a reduction of nuclear R-loops in patient fibroblasts and motor neurons.<sup>11</sup> R-loops are three-stranded nucleic acid structures that form when nascent RNA hybridizes with its template DNA to form an RNA-DNA hybrid and displaces the non-template DNA strand. Senataxin is a helicase that resolves R-loops.<sup>19,20</sup> An antibody, S9.6, is used in many studies to characterize R-loops.<sup>21</sup> To demonstrate the specificity and sensitivity of the S9.6 antibody for R-loops, we first probed synthetic hybrids of dsRNA, dsDNA, or RNA-DNA hybrid with the S9.6 antibody (Fig 5A). S9.6 signal was specific to RNA-DNA hybrid, and signal intensity was reduced with decreasing amounts of RNA-DNA hybrid. We evaluated R-loop abundance in the Glu385Lys

Author Manuscript

patient fibroblasts and found a significant decrease compared to controls by S9.6 dot blot ( $p < 0.05$ ) (Fig 5B).

To confirm that the reduction in R-loop abundance is a consequence of the SETX variant, we overexpressed the wild-type and mutant forms of SETX in control fibroblasts.

Overexpression of the Glu385Lys and Leu389Ser mutations resulted in a significant reduction in nuclear R-loop structure by immunofluorescence compared to transfection of WT senataxin alone ( $p < 0.01$ ; Fig 5C). Overexpression of a 500 amino acid N-terminal WT fragment of senataxin without the helicase domain or other non-pathogenic variants with high allele frequency (Lys827Glu, ExAC allele frequency 0.001) did not reduce R-loop levels. Dot blot analysis of cells overexpressing SETX variants, including the previously reported Arg2136His ALS4 variant<sup>5</sup>, showed a reduction in S9.6 signal intensity when compared to WT SETX (Fig 5D).

## Discussion

Defining the appropriate molecular and clinical biomarkers for disease characterization and progression are crucial steps to understanding and treating neurological disease. In this study, we identified clinical and molecular characteristics of ALS4 caused by heterozygous mutations in the *SETX* gene.

Relative to other forms of ALS, the onset for ALS4 is early. The average age of onset in our cohort is 17 years old which is consistent with the previous clinical characterization of patients with mutation at codon 389 of SETX.<sup>6,22</sup> In ALS4, males are more affected than females. Rafiq et al. also found a significantly greater increase in male ALS patient serum CK

levels compared to females.<sup>23</sup> A previous study of ALS4 patients found a higher percentage of asymptomatic females (31%) compared to males (13%).<sup>6</sup>

As a motor neuron disease, ALS4 leads to progressive muscle loss. We found significantly higher serum CK and lower creatinine levels. Elevation of serum CK levels is also known to occur in patients with sporadic ALS.<sup>23</sup> Among our ALS4 cohort, the male patients have significantly lower creatinine levels which reflects a greater disease burden in males. Serum creatinine level have been reported to change significantly during the progression of other motor neuron diseases.<sup>24,25</sup> Radiological studies showed higher thigh muscle fat fraction and lower lean body mass. ALS4 patients have fatty infiltration in the muscles of their lower extremities. Previously, we found a reduction in contractile muscle volume in a smaller cohort of ALS4 patients.<sup>11</sup> The pattern of lean body mass on DEXA analysis supports that the lower extremities are more severely affected than the upper extremities. Manual muscle testing also showed a reduction in lower leg strength with disease duration. The greater severity of lower extremity involvement in ALS4 was first described by Rabin et al., 1999.<sup>6</sup> The increased fat replacement of muscle is likely related to a loss of lean body mass and disuse, and has been found to correlate with disease status in other studies.<sup>26</sup> Together these data suggest MRI of the lower leg for fatty infiltration to the muscles may be a useful study to follow for evidence of disease progression.

We found a similar pattern of clinical and radiological changes in a patient with mutation in SETX codon 385. Consistent with the gain of function in SETX helicase activity and reduction in R-loop levels that had been detected in patients with mutation at Leu389Ser,<sup>11</sup> the Glu385Lys SETX variant was also associated with a reduction in R-loop levels. Expression

levels of BAMBI, a negative regulator of TGF $\beta$  activity, were also found to be reduced in the Glu385Lys SETX patient fibroblasts.

SETX function has been shown to modulate neuromuscular junction plasticity in *Drosophila* through the TGF $\beta$  pathway.<sup>27</sup> TGF signaling has been found to inhibit neurite elongation and branching in neuronal cell models<sup>28</sup>, and to promote disease progression in the SOD1 mouse model of ALS by disrupting the neuroprotective functions of activated glial and immune cells.<sup>29</sup> Here, we show that exogenous TGF $\beta$  treatment of control iPSC-derived motor neurons resulted in a reduction in motor neuron neurite length and branching, indicating that activation of the TGF $\beta$  pathway adversely affects motor neurons.

In conclusion, this study of 32 subjects with mutations in senataxin establishes the clinical and molecular features of an inherited form of upper and lower motor neuron disease. We also developed measurement of R-loop levels and BAMBI expression as assays for interrogating the potential pathogenicity of *SETX* variants. Further studies with other mutations in the *SETX* gene causing ALS4 are needed to more thoroughly evaluate the clinical and molecular spectrum. Additional longitudinal data are also needed to determine the clinical course, molecular effects and assess heterogeneity of the disease.

**Acknowledgements:** We thank Dr. Stephen Leppla for the S9.6 antibody. We thank Ms. Elizabeth Hartnett for her help in scheduling patients during the study and the clinical staff of the outpatient NIH neurology clinic for assistance during the patients' visits. We thank the National Institutes of Health NHLBI iPSC cell core facility for the generation of stem cell lines. We thank the Howard Hughes Medical Institute and intramural National Institute of Neurological Disorders and Stroke for funding this work. We are grateful for the active participation of the

patients and their families; without their involvement and encouragement this project would not have been possible.

**Author Contributions:** C.G., K.H.F., and V.G.C. contributed to the conception and design of the study. C.G., A.P., J.A., P.R., D.L., J.A.W., and A.B.S. contributed to the acquisition and analysis of data. C.G., K.H.F., and V.G.C. contributed to drafting the manuscript and figures.

**Potential Conflicts of Interest:** Nothing to report.

## References

1. Ghasemi M, Brown RH Jr. Genetics of Amyotrophic Lateral Sclerosis. *Cold Spring Harb Perspect Med* 2018;8:5.
2. Gitcho MA, Baloh RH, Chakraverty S et al. TDP-43 A315T mutation in familial motor neuron disease. *Ann Neurol* 2008;63:535-538.
3. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. *Science* 2009;323:1205-1208.
4. Kim HJ, Kim NC, Wang YD et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. *Nature* 2013;495:467-473.
5. Chen YZ, Bennett CL, Huynh HM et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). *Am J Hum Genet* 2004;74:1128-1135.
6. Rabin BA, Griffin JW, Crain BJ et al. Autosomal dominant juvenile amyotrophic lateral sclerosis. *Brain* 1999;122:1539-1550.
7. Hirano M, Quinzii CM, Mitsumoto H et al. Senataxin mutations and amyotrophic lateral sclerosis. *Amyotroph Lateral Scler* 2011;12:223-227.
8. Bassuk AG, Chen YZ, Batish SD et al. In cis autosomal dominant mutation of senataxin associated with tremor/ataxia syndrome. *Neurogenetics* 2007;8:45-49.
9. Phansalkar, N; More, S & Sabale, A et al. Adaptive local thresholding for detection of nuclei in diversity stained cytology images. *International Conference on Communications and Signal Processing (ICCSP)* 2011;218-220.
10. Kelly TL, Wilson KE, Heymfield SB. Dual energy X-Ray absorptiometry body composition reference values from NHANES. *PLoS One* 2009;4:e7038.
11. Grunseich C, Wang IX, Watts JA et al. Senataxin mutation reveals how R-loops promote transcription by blocking DNA methylation at gene promoters. *Mol Cell* 2018;69:426-437.
12. Fernandopulle MS, Prestil R, Grunseich C, Wang C, Gan L, Ward ME. Transcription factor-mediated differentiation of human iPSCs into neurons. *Curr Protoc Cell Biol.* 2018;79:e51
13. Haruki M, Noguchi E, Kanaya S, Crouch RJ. Kinetic and stoichiometric analysis for the binding of Escherichia coli ribonuclease HI to RNA-DNA hybrids using surface plasmon resonance. *J Biol Chem* 1997;272:22015-22022.

14. Cancer facts and figures 2019, American Cancer Society.  
[www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf](http://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf) Updated 2019. Accessed July 1, 2019
15. The cancer genome atlas, National human genome research institute,  
[www.cancergenome.nih.gov](http://www.cancergenome.nih.gov) Updated 2019. Accessed June 1, 2018
16. Cerbini T, Funahashi R, Luo Y et al. Transcription activator-like effector nuclease (TALEN)-mediated CLYBL targeting enables enhanced transgene expression and one-step generation of dual reporter human induced pluripotent stem cell (iPSC) and neural stem cell (NSC) lines. *PLoS One* 2015;10:e0116032.
17. Arber S, Han B, Mendelsohn M, Smith M, Jessell TM, Sockanathan S. Requirement for the homeobox gene Hb9 in the consolidation of motor neuron identity. *Neuron* 1999;23:659-674.
18. Carriedo SG, Yin HZ, Weiss JH. Motor neurons are selectively vulnerable to AMPA/kainite receptor-mediated injury in vitro. *J Neurosci* 1996;16:4069-4079.
19. Kim HD, Choe J, Seo YS. The *sen1(+)* gene of *Schizosaccharomyces pombe*, a homologue of budding yeast *SEN1*, encodes an RNA and DNA hemicase. *Biochemistry* 1999;38:14697-14710.
20. Skourti-Stathaki K, Proudfoot NJ, Gromak N. Human senataxin resolves RNA/DNA hybrids formed at transcriptional pause sites to promote Xrn2-dependent termination. *Mol Cell* 2011;42:794-805.
21. Hu Z, Zhang A, Storz G, Gottesman S, Leppla SH. An antibody-based microarray assay for small RNA detection. *Nucleic Acids Res* 2006;34:e52.
22. Avemaria F, Lunetta C, Tarlarini C, et al. Mutation in the senataxin gene found in a patient affected by familial ALS with juvenile onset and slow progression. *Amyotroph Lateral Scler* 2011;12:228-230.
23. Rafiq MK, Lee E, Bradburn M, McDermott CJ, Shaw PJ. Creatine kinase enzyme level correlates positively with serum creatinine and lean body mass, and is a prognostic factor for survival in amyotrophic lateral sclerosis. *Eur J Neurol* 2016;23:1071-1078.
24. Patin F, Corcia P, Madji Hounoum B, et al. Biological follow-up in amyotrophic lateral sclerosis: decrease in creatinine levels and increase in ferritin levels predict poor prognosis. *Eur J Neurol* 2015;22:1385-1390.
25. Hashizume A, Katsuno M, Banno H et al. Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy. *Brain* 2012;135:2838-2848.

26. Dahlqvist JR, Oestergaard ST, Poulsen NS, Thomsen C, Vissing J. Refining the spinobulbar muscular atrophy phenotype by quantitative MRI and clinical assessments. *Neurology* 2019;92:e548-e559.
27. Mushtaq Z, Choudhury SD, Gangwar SK, Orso G, Kumar V. Human senataxin modulates structural plasticity of the neuromuscular junction in drosophila through a neuronally conserved TGF $\beta$  signaling pathway. *Neurodegener Dis* 2016;16:324-336.
28. Nakashima H, Tsujimura K, Irie K, et al. Canonical TGF- $\beta$  signaling negatively regulates neuronal morphogenesis through TGFIF/Smad complex-mediated CRMP2 suppression. *J Neurosci* 2018;38:4791-4810.
29. Endo F, Komine O, Fujimori-Tonou N et al. Astrocyte-derived TGF- $\beta$ 1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells. *Cell Rep* 2015;11:592-604.



## Legend

**Figure 1:** Glu385Lys mutation in senataxin (SETX). (A) The amino acid sequence at position 385 of SETX is conserved across species. (B) Map of helicase domain and nuclear localization signal (NLS) showing the location of the three previously known mutations causing ALS4 (Tyr3Ile, Leu389Ser, and Arg2136His) and the Glu385Lys variant. (C) Western blot of SETX from fibroblast cultures of two controls and the Glu385Lys patient. Vinculin was used as a loading control. (D) Immunofluorescence staining for SETX (green) in two controls and patient fibroblasts. DAPI staining in blue. Scale bar, 5 $\mu$ m. (E) Atrophy in the interossei muscles of the hand and involuntary abduction of the fifth finger.

**Figure 2:** Clinical measurements in ALS4 patients with mutation at codon 389. (A) T1 MRI image of the thigh muscle with segmented non-contractile tissue in black. Compact bone and bone marrow removed from fat fraction calculation. (B) Disease duration is significantly correlated with MRI muscle fat fraction from the thigh ( $R^2 = 0.35$ ;  $p = 0.01$ ) and lower leg ( $R^2 = 0.49$ ;  $p < 0.01$ ). (C) Dual-energy X-ray absorptiometry imaging in an ALS4 patient showing relative preservation of lean body mass (red) in the upper compared to the lower extremities. (D) Distribution of Z-scores shows a significant reduction in appendicular lean body mass (-1.7) and increase (E) in average leg (2.1) vs. arm (0.6) fat Z-scores. Z-scores calculated using National Health and Nutrition Examination Survey (NHANES) reference controls. Black dotted line indicates the Z-score 1 standard deviation below (D) or above (E) the mean. (F) T1 MRI imaging of the thigh showing fatty infiltration and loss of contractile tissue in the thigh (left) and lower leg (right).

**Figure 3:** TGF $\beta$  activity in patient fibroblasts and motor neuron characterization. (A) Reduced *BAMBI* transcript expression in Glu385Lys patient fibroblasts compared to 2 controls. Error bars are SEM of triplicates. \*\* $p < 0.01$  (t test). (B) Immunofluorescence staining from three control iPSC cell lines differentiated by expression of the human Neurogenin 2, Islet 1, and LIM Homeobox 3 (hNIL) transgene cassette. HB9 staining (green) in motor neuron nuclei, SMI-32 (cyan) in motor neuron processes, DAPI staining in blue. Staining is at 5 days post differentiation. Scale bar, 25 $\mu$ m. (C) Western blot analysis of pSMAD2 and SMAD2/3 levels in iPSC motor neurons treated with 0, 5, and 20 ng/mL TGF $\beta$ .

**Figure 4:** Morphological analysis of TGF $\beta$  treated motor neurons. (A) Fluorescence imaging of control motor neuron lines with and without TGF $\beta$  treatment. TGF $\beta$  treated motor neurons have reduced neurite length (B) and branching (C). N= 6, 5 wells analyzed per sample, error bars are SEM. Scale bar, 50 $\mu$ m. error bars are SEM. \*\*\*\* $p < 0.0001$ ; (t test).

**Figure 5:** R-loop assessments of senataxin dysfunction. (A) S9.6 antibody dot blot against a dilution series of synthetic dsRNA, dsRNA, and RNA/DNA hybrids. (B) Dot blot probed with S9.6 antibody shows fewer R-loops in Glu385Lys patient fibroblasts compared to two age and sex matched controls. A duplicate blot probed with anti-dsDNA antibody was used as loading control. Error bars are SEM of triplicates. \* $p < 0.05$  (t test). (C) Immunofluorescence staining showing reduced nuclear S9.6 (green) in cells transfected with Leu389Ser and Glu385Lys forms of SETX compared to WT. Scale bar, 5 $\mu$ m, R-loops in nuclei indicated by arrow. 10 fields per sample, 15-20 cells per field; error bars are SEM. \*\*\*\* $p < 0.0001$ ; \*\* $p < 0.01$  (t test). (D) Quantification of dot blot S9.6 signal in cells transfected with WT, Leu389Ser, Glu385Lys, and

Arg2136His forms of SETX. Samples normalized to dsDNA loading control. Error bars are SEM of triplicates. \*p < 0.05, \*\*p < 0.01 (t test).

## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 1. Identifying Information

1. Given Name (First Name) Joshua      2. Surname (Last Name) Amaya      3. Date 10/18/19
4. Are you the corresponding author?     Yes     No
5. Manuscript Title  
Clinical and Molecular consequences of senataxin mutations
6. Manuscript Identifying Number (if you know it)  
ANA-19-1334

### Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest?     Yes     No

### Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication.**

Are there any relevant conflicts of interest?     Yes     No

### Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?     Yes     No

## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- Yes, the following relationships/conditions/circumstances are present (explain below):
- No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

### Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

### Evaluation and Feedback

Please visit <http://www.icmje.org/cgi-bin/feedback> to provide feedback on your experience with completing this form.



## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 1. Identifying Information

1. Given Name (First Name)

Vivian

2. Surname (Last Name)

Cheung

3. Date

10/18/2019

4. Are you the corresponding author?

Yes  No

5. Manuscript Title

Clinical and molecular consequences of senataxin mutations

6. Manuscript Identifying Number (if you know it)

### Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest?  Yes  No

### Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication.

Are there any relevant conflicts of interest?  Yes  No

### Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?  Yes  No

## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- Yes, the following relationships/conditions/circumstances are present (explain below):
- No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

### Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

N/A.

### Evaluation and Feedback

Please visit <http://www.icmje.org/cgi-bin/feedback> to provide feedback on your experience with completing this form.



## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 1. Identifying Information

1. Given Name (First Name) Dongjun      2. Surname (Last Name) Li      3. Date 10/18/19
4. Are you the corresponding author?     Yes     No
5. Manuscript Title  
Clinical and molecular consequences of senataxin mutations
6. Manuscript Identifying Number (if you know it)

### Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest?     Yes     No

### Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication.**

Are there any relevant conflicts of interest?     Yes     No

### Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?     Yes     No



## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- Yes, the following relationships/conditions/circumstances are present (explain below):
- No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.


### Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

### Evaluation and Feedback


Please visit <http://www.icmje.org/cgi-bin/feedback> to provide feedback on your experience with completing this form.

Figure 5




ANA\_25681\_Figure5#3.tif

Figure 1




ANA\_25681\_Figure 1.tif

Figure 2




ANA\_25681\_Figure 2.tif

Figure 3



ANA\_25681\_Figure 3#2-01.tif

Figure 4



ANA\_25681\_Figure 4.tif

## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 1. Identifying Information

1. Given Name (First Name)  
Kenneth
2. Surname (Last Name)  
Fischbeck
3. Date  
Oct 18, 2019
4. Are you the corresponding author?  Yes  No
5. Manuscript Title  
*Clinical and Molecular consequences of senataxin mutations*
6. Manuscript Identifying Number (if you know it)

### Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest?  Yes  No

### Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication.**

Are there any relevant conflicts of interest?  Yes  No

### Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?  Yes  No



## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- Yes, the following relationships/conditions/circumstances are present (explain below):
- No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

### Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

### Evaluation and Feedback

Please visit <http://www.icmje.org/cgi-bin/feedback> to provide feedback on your experience with completing this form.



## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 1. Identifying Information

1. Given Name (First Name) Christopher      2. Surname (Last Name) Grunseich      3. Date 10/18/2019
4. Are you the corresponding author?     Yes     No
5. Manuscript Title  
Clinical and Molecular consequences of senataxin mutations
6. Manuscript Identifying Number (if you know it)

### Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest?     Yes     No

### Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication.**

Are there any relevant conflicts of interest?     Yes     No

### Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?     Yes     No



## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- Yes, the following relationships/conditions/circumstances are present (explain below):  
 No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

### Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

No conflicts of interest

### Evaluation and Feedback

Please visit <http://www.icmje.org/cgi-bin/feedback> to provide feedback on your experience with completing this form.

## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 1. Identifying Information

1. Given Name (First Name)

Aneesh

2. Surname (Last Name)

Patankar

3. Date

10/20/19

4. Are you the corresponding author?

Yes  No

5. Manuscript Title

Clinical and Molecular consequences of senataxin mutations

6. Manuscript Identifying Number (if you know it)

### Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest?  Yes  No

### Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication.**

Are there any relevant conflicts of interest?  Yes  No

### Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?  Yes  No



## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- Yes, the following relationships/conditions/circumstances are present (explain below):
- No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

### Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

### Evaluation and Feedback

Please visit <http://www.icmje.org/cgi-bin/feedback> to provide feedback on your experience with completing this form.



## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 1. Identifying Information

1. Given Name (First Name)  
Prisila

2. Surname (Last Name)  
Ramirez

3. Date  
10/18/19

4. Are you the corresponding author?  Yes  No

5. Manuscript Title

*Clinical and Molecular consequences of senataxin mutations*

6. Manuscript Identifying Number (if you know it)

### Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest?  Yes  No

### Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication.**

Are there any relevant conflicts of interest?  Yes  No

### Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?  Yes  No

## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- Yes, the following relationships/conditions/circumstances are present (explain below):
- No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

### Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

### Evaluation and Feedback

Please visit <http://www.icmje.org/cgi-bin/feedback> to provide feedback on your experience with completing this form.

## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 1. Identifying Information

1. Given Name (First Name)

Alice

2. Surname (Last Name)

Schindler

3. Date

10/22/19

4. Are you the corresponding author?

Yes

No

5. Manuscript Title

Clinical and Molecular consequences of senataxin mutations

6. Manuscript Identifying Number (if you know it)

### Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest?

Yes

No

### Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest?

Yes

No

### Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?

Yes

No

## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- Yes, the following relationships/conditions/circumstances are present (explain below):
- No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

### Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

### Evaluation and Feedback

Please visit <http://www.icmje.org/cgi-bin/feedback> to provide feedback on your experience with completing this form.



## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 1. Identifying Information

1. Given Name (First Name) Jason      2. Surname (Last Name) Watts      3. Date 10/18/19
4. Are you the corresponding author?     Yes     No
5. Manuscript Title  
Clinical and Molecular consequences of senataxin mutations
6. Manuscript Identifying Number (if you know it)  
\_\_\_\_\_

### Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest?     Yes     No

### Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication.**

Are there any relevant conflicts of interest?     Yes     No

### Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?     Yes     No



## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- Yes, the following relationships/conditions/circumstances are present (explain below):
- No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

### Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

### Evaluation and Feedback

Please visit <http://www.icmje.org/cgi-bin/feedback> to provide feedback on your experience with completing this form.